The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Interim results of aasur: A single arm, multi-center phase 2 trial of apalutamide (A) + abiraterone acetate + prednisone (AA+P) + leuprolide with stereotactic ultra-hypofractionated radiation (UHRT) in very high risk (VHR), node negative (N0) prostate cancer (PCa).
 
Sean Matthew McBride
Consulting or Advisory Role - AstraZeneca; Janssen
Research Funding - Genentech
 
Daniel Eidelberg Spratt
Consulting or Advisory Role - AstraZeneca; Blue Earth Diagnostics; Boston Scientific; Janssen Oncology
 
Marisa Kollmeier
No Relationships to Disclose
 
Wassim Abida
Honoraria - Aptitude Health; CARET; Medscape; Roche
Consulting or Advisory Role - Clovis Oncology; Daiichi Sankyo; Janssen; MORE Health; ORIC Pharmaceuticals
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); ORIC Pharmaceuticals (Inst); Zenith Epigenetics (Inst)
Travel, Accommodations, Expenses - Clovis Oncology; GlaxoSmithKline; ORIC Pharmaceuticals
 
Han Xiao
No Relationships to Disclose
 
Susan F. Slovin
Consulting or Advisory Role - Bayer; Clovis Oncology; Pfizer
Speakers' Bureau - OncLive; PER; Prime Oncology; Society for Immunotherapy of Cancer
Research Funding - AstraZeneca
 
Channing Judith Paller
Consulting or Advisory Role - Dendreon; Exelixis; Omnitura
Research Funding - Lilly (Inst)
 
Curtiland Deville
No Relationships to Disclose
 
Robert Benjamin Den
Employment - Alpha TAU; Alpha TAU
 
Jason W.D. Hearn
No Relationships to Disclose
 
Howard I. Scher
Leadership - Asterias Biotherapeutics
Stock and Other Ownership Interests - Asterias Biotherapeutics
Consulting or Advisory Role - Ambry Genetics/Konica Minolta; Amgen; Bayer; ESSA; Janssen; Janssen Research & Development; Menarini Silicon Biosystems; Pfizer; Sun Pharma; WIRB-Copernicus Group
Research Funding - Epic Sciences (Inst); Illumina (Inst); Janssen (Inst); Menarini Silicon Biosystems (Inst); Thermofisher Scientific Biomarkers (Inst)
Patents, Royalties, Other Intellectual Property - BioNTech -Intellectual Property Rights; Elucida Oncology - Intellectual Property Rights; MabVAX - Intellectual Property Rights; Y-mAbs Therapeutics, Inc - Intellectual Property Rights
Travel, Accommodations, Expenses - Amgen; Asterias Biotherapeutics; Bayer; ESSA; Konica Minolta; Menarini Silicon Biosystems; Phosplatin Therapeutics; Prostate Cancer Foundation; Sanofi; WIRB-Copernicus Group
 
Michael J. Zelefsky
Honoraria - Accuray
Consulting or Advisory Role - Alpha Tau; Augmenix; Boston Scientific
Patents, Royalties, Other Intellectual Property - Ferring provided partial funding for a clinical trial (Inst)
Other Relationship - Editor in Chief for Brachytherapy
 
Dana E. Rathkopf
Consulting or Advisory Role - AstraZeneca; Bayer; Genentech; Janssen; Myovant Sciences
Research Funding - AstraZeneca (Inst); Bayer (Inst); Celgene (Inst); Ferring (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Medivation (Inst); Millennium (Inst); Novartis (Inst); Phosplatin Therapeutics (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TRACON Pharma (Inst)